---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-283351"
form_type: "8-K"
ticker: "BNTC"
cik: "0001808898"
company_name: "Benitec Biopharma Inc."
filed_at: "2025-11-14T23:59:59+00:00"
generated_at: "2026-05-16T19:54:17.635363+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Benitec Q1 net loss $9.0M; BB-301 100% responder rate; FDA Fast Track; raised $100M

## Summary
- Net loss of $9.0M ($0.22/sh) vs $5.1M ($0.18) YoY; total expenses $9.8M, up from $5.8M.
- All 6 Cohort 1 patients in BB-301 Phase 1b/2a met formal response criteria (100% responder rate).
- FDA granted Fast Track Designation for BB-301; first Cohort 2 patient dosed in Q4 2025.
- Raised ~$100M in oversubscribed equity offering at $13.50/sh; cash $94.5M at Sep 30.
- Appointed Sharon Mates (ex-CEO Intra-Cellular Therapies) to Board of Directors.

## SEC filing metadata
- accession: 0001193125-25-283351
- form_type: 8-K
- ticker: BNTC
- cik: 0001808898
- company_name: Benitec Biopharma Inc.
- filed_at: 2025-11-14T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1808898/000119312525283351/0001193125-25-283351-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1808898/000119312525283351/d811784d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-283351
- JSON: https://secwatch.observer/filing/0001193125-25-283351.json
- Plain text: https://secwatch.observer/filing/0001193125-25-283351.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.